{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05883449",
            "orgStudyIdInfo": {
                "id": "AFM13-203"
            },
            "organization": {
                "fullName": "Affimed GmbH",
                "class": "INDUSTRY"
            },
            "briefTitle": "Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL",
            "officialTitle": "A Phase 2, Open-Label, Multi-Center Study of Innate Cell Engager AFM13 in Combination With Allogeneic Natural Killer Cells (AB-101) in Subjects With Recurrent or Refractory Hodgkin Lymphoma and CD-30 Positive Peripheral T-Cell Lymphoma",
            "acronym": "LuminICE-203",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "phase-study-of-in-combination-with-ab-in-subjects-with-r-r-hl-and-ptcl"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-10-10",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-04-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-11-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-05-19",
            "studyFirstSubmitQcDate": "2023-05-30",
            "studyFirstPostDateStruct": {
                "date": "2023-06-01",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-29",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-30",
                "type": "ESTIMATED"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Affimed GmbH",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Artiva Biotherapeutics, Inc.",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "AFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts. The study is evaluating the safety and efficacy of AFM13 in combination with AB-101 in subjects with R/R classical HL and CD30-positive PTCL.",
            "detailedDescription": "The study will start with a safety run-in exploring AFM13/AB-101 combination treatment in subjects with classical HL. Two dose levels of AFM13 and AB-101, respectively, will be tested in 4 cohorts. Cohort 1 and 2 will enroll in parallel. Enrolment into Cohort 3 and 4 will start only if the combination treatment has been well tolerated.\n\nFollowing the safety run-in observation period, a thorough risk-benefit analysis will be performed to determine 2 of the 4 cohorts/dose levels that will be further evaluated in the main part of the study which will also include subjects with classical HL and will follow a Simon two-stage design.\n\nAn additional exploratory cohort (Cohort 5) will enroll subjects with select CD30-positive PTCL subtypes after completion of the safety run-in.\n\nAll subjects will be treated with AFM13/AB-101 for a maximum of 3 cycles (cycle length is 48-days)."
        },
        "conditionsModule": {
            "conditions": [
                "Relapsed or Refractory Hodgkin Lymphoma",
                "Peripheral T Cell Lymphoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 154,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Safety run-in in Hodgkin Lymphoma",
                    "type": "EXPERIMENTAL",
                    "description": "4 safety run-in cohorts:\n\n* Cohort 1: 200 mg AFM13 + AB-101 (2 \u00d7 10e9 cells on Day 1, Day 8, Day 15)\n* Cohort 2: 300 mg AFM13 + AB-101 (2 \u00d7 10e9 cells on Day 1, Day 8, Day 15)\n* Cohort 3: 200 mg AFM13 + AB-101 (4 \u00d7 10e9 cells on Day 1; 2 \u00d7 10e9 cells on Day 8, Day 15)\n* Cohort 4: 300 mg AFM13 + AB-101 (4 \u00d7 10e9 cells on Day 1; 2 \u00d7 10e9 cells on Day 8, Day 15)",
                    "interventionNames": [
                        "Drug: AFM13",
                        "Drug: AB-101",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine",
                        "Drug: Interleukin-2"
                    ]
                },
                {
                    "label": "Dose Level A in Hodgkin Lymphoma",
                    "type": "EXPERIMENTAL",
                    "description": "Randomized Simon 2-stage design in Hodgkin Lymphoma Dose Level A (selected from cohort 1-4 of Safety run-in)",
                    "interventionNames": [
                        "Drug: AFM13",
                        "Drug: AB-101",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine",
                        "Drug: Interleukin-2"
                    ]
                },
                {
                    "label": "Dose Level B in Hodgkin Lymphoma",
                    "type": "EXPERIMENTAL",
                    "description": "Randomized Simon 2-stage design in Hodgkin Lymphoma Dose Level B (selected from cohort 1-4 of Safety run-in)",
                    "interventionNames": [
                        "Drug: AFM13",
                        "Drug: AB-101",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine",
                        "Drug: Interleukin-2"
                    ]
                },
                {
                    "label": "Exploratory: AFM13 + AB-101 on CD30-positive PTCL",
                    "type": "EXPERIMENTAL",
                    "description": "AFM13 + AB-101 on select CD30-positive PTCL subtypes (Dose Level A or B)",
                    "interventionNames": [
                        "Drug: AFM13",
                        "Drug: AB-101",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine",
                        "Drug: Interleukin-2"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "AFM13",
                    "description": "anti-human CD30 \u00d7 anti-human CD16A recombinant antibody therapy, intravenous infusion",
                    "armGroupLabels": [
                        "Dose Level A in Hodgkin Lymphoma",
                        "Dose Level B in Hodgkin Lymphoma",
                        "Exploratory: AFM13 + AB-101 on CD30-positive PTCL",
                        "Safety run-in in Hodgkin Lymphoma"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "AB-101",
                    "description": "NK cell therapy, intravenous infusion",
                    "armGroupLabels": [
                        "Dose Level A in Hodgkin Lymphoma",
                        "Dose Level B in Hodgkin Lymphoma",
                        "Exploratory: AFM13 + AB-101 on CD30-positive PTCL",
                        "Safety run-in in Hodgkin Lymphoma"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cyclophosphamide",
                    "description": "Lymphodepleting chemotherapy, intravenous infusion",
                    "armGroupLabels": [
                        "Dose Level A in Hodgkin Lymphoma",
                        "Dose Level B in Hodgkin Lymphoma",
                        "Exploratory: AFM13 + AB-101 on CD30-positive PTCL",
                        "Safety run-in in Hodgkin Lymphoma"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Fludarabine",
                    "description": "Lymphodepleting chemotherapy, intravenous infusion",
                    "armGroupLabels": [
                        "Dose Level A in Hodgkin Lymphoma",
                        "Dose Level B in Hodgkin Lymphoma",
                        "Exploratory: AFM13 + AB-101 on CD30-positive PTCL",
                        "Safety run-in in Hodgkin Lymphoma"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Interleukin-2",
                    "description": "Immune cytokine, subcutaneously",
                    "armGroupLabels": [
                        "Dose Level A in Hodgkin Lymphoma",
                        "Dose Level B in Hodgkin Lymphoma",
                        "Exploratory: AFM13 + AB-101 on CD30-positive PTCL",
                        "Safety run-in in Hodgkin Lymphoma"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Objective Response Rate by Independent Radiology Committee",
                    "description": "ORR (complete response (CR) + partial response \\[PR\\]) by Independent Radiology Committee (IRC) based on positron emission tomography-computed tomography (PET-CT) as assessed by the Lugano classification",
                    "timeFrame": "From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Duration of Response by Investigator and Independent Radiology Committee",
                    "description": "Duration of response (DOR) defined as time from first assessment of PR or CR to the first assessment of progressive disease. Response based on positron emission tomography-computed tomography (PET-CT) as assessed by the Lugano classification.",
                    "timeFrame": "Tumor assessment performed every 6 weeks for 3 cycles, if no disease progression on completion of treatment, then every 3 months for the first 12 months and then every 6 months (up to 24 months)"
                },
                {
                    "measure": "Complete response rate (CRR) by Investigator and Independent Radiology Committee",
                    "description": "Complete Response Rate based on positron emission tomography-computed tomography (PET-CT) as assessed by the Lugano classification.",
                    "timeFrame": "Tumor assessment performed every 6 weeks for 3 cycles, if no disease progression on completion of treatment, then every 3 months for the first 12 months and then every 6 months (up to 24 months)"
                },
                {
                    "measure": "ORR by Investigator based on PET-CT as assessed by the Lugano classification",
                    "description": "ORR (CR + PR) by Investigator based on positron emission tomography-computed tomography (PET-CT) as assessed by the Lugano classification",
                    "timeFrame": "Tumor assessment performed every 6 weeks for 3 cycles, if no disease progression on completion of treatment, then every 3 months for the first 12 months and then every 6 months (up to 24 months)"
                },
                {
                    "measure": "Incidence of subjects receiving subsequent transplant",
                    "description": "The incidence of subjects receiving subsequent transplant will be assessed and summarized by percentage rates and 95% Confidence Intervals",
                    "timeFrame": "Throughout study completion (estimated up to 24 months)"
                },
                {
                    "measure": "Incidence of TEAEs and SAEs",
                    "description": "Frequency of subjects with study-drug related treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)",
                    "timeFrame": "From the time of first protocol-specific intervention until 30 days after the last administration"
                },
                {
                    "measure": "Immunogenicity assessment of AFM13 in combination with AB-101",
                    "description": "Frequency of subjects developing anti-drug antibodies (ADAs) against AFM13 or AB-101",
                    "timeFrame": "During treatment cycles (estimated up 6 months)"
                },
                {
                    "measure": "Progression-free survival (PFS) by Independent Radiology Committee",
                    "description": "Progression-free survival (PFS) defined as time from first treatment (AFM13/AB-101) received until PD/OS.",
                    "timeFrame": "Throughout study completion (estimated up to 24 months)"
                },
                {
                    "measure": "Overall survival (OS)",
                    "description": "Overall survival rate",
                    "timeFrame": "up to 24 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Subjects with a diagnosis of FDG-avid relapsed or refractory classical HL OR select subtypes of FDG-avid CD30-positive relapsed or refractory PTCL\n* For subjects with R/R PTCL a pre-enrollment tumor biopsy positive for CD30 locally assessed by Ber-H2 targeted immunohistochemistry at \u22651% is mandatory (PTCL subtypes: PTCL-NOS, Angioimmunoblastic T-cell lymphoma, ALCL, anaplastic lymphoma kinase (ALK)-positive, ALCL, ALK-negative)\n* Subjects with R/R classical HL must have received at least two lines of therapy including one prior line of combination chemotherapy. Prior therapy must also have included brentuximab vedotin and a PD1 check point inhibitor.\n* Subjects with R/R PTCL must have received at least one prior line of combination chemotherapy. Subjects with ALCL subtype of PTCL must have received or been intolerant to brentuximab vedotin.\n* Subjects with R/R classical HL AND R/R PTCL: Prior ASCT is permitted if completed at least 3 months prior to the first dose of study treatment. Prior allogeneic stem cell transplantation will be permitted if completed at least 1 year from study enrollment and there are no signs or symptoms of GVHD. Prior CAR-T therapy is permitted if last CAR-T dose completed at least 6 months prior to the first dose of study treatment.\n* Ability to understand and sign the ICF\n\nExclusion Criteria:\n\n* Active central nervous system (CNS) involvement (untreated or uncontrolled parenchymal brain metastasis or positive cytology of cerebrospinal fluid)\n* Previous treatment with AFM13 or CBNK cells\n* History of a solid organ allograft, or an inflammatory or autoimmune disease likely to be exacerbated by IL-2 (including subjects requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease that may require systemic steroids or immunosuppressive agents\n* Treatment with any therapeutic mAb or immunosuppressive medications\n* Known active Hepatitis B or C defined per protocol\n* Active HIV Infection\n* History of any other systemic malignancy, unless previously treated with curative intent and the subject has been disease free for 2 years or longer\n* Active acute or chronic graft vs. host disease (GVHD) or GVHD requiring immunosuppressive treatment, clinically significant central nervous system (CNS) dysfunction",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Affimed GmbH",
                    "role": "CONTACT",
                    "phone": "004962216743",
                    "phoneExt": "60",
                    "email": "trials@affimed.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Wunderle Lydia, MD",
                    "affiliation": "Affimed Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "O'Neal Comprehensive Cancer Center at UAB",
                    "status": "RECRUITING",
                    "city": "Birmingham",
                    "state": "Alabama",
                    "zip": "35294",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Christopher Crawford Jr.",
                            "role": "CONTACT",
                            "email": "chriscrawford@uabmc.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.52066,
                        "lon": -86.80249
                    }
                },
                {
                    "facility": "City of Hope National Medical Center",
                    "status": "RECRUITING",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Matthew Mei, MD",
                            "role": "CONTACT",
                            "email": "mamei@coh.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "UC Irvine Health",
                    "status": "RECRUITING",
                    "city": "Orange",
                    "state": "California",
                    "zip": "92868",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Lauren Pinter-Brown, MD",
                            "role": "CONTACT",
                            "email": "lpinterb@hs.uci.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.78779,
                        "lon": -117.85311
                    }
                },
                {
                    "facility": "Sarah Cannon Research Institute",
                    "status": "RECRUITING",
                    "city": "Denver",
                    "state": "Colorado",
                    "zip": "80218",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "844-482-4812"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.73915,
                        "lon": -104.9847
                    }
                },
                {
                    "facility": "Norton Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Louisville",
                    "state": "Kentucky",
                    "zip": "40207",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Tabby Thomas",
                            "role": "CONTACT",
                            "phone": "502-899-3366",
                            "email": "StudyStartup@NCIResearch.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.25424,
                        "lon": -85.75941
                    }
                },
                {
                    "facility": "Beth Israel Deaconess Medical",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "John Fisher",
                            "role": "CONTACT",
                            "email": "jfisher6@bidmc.harvard.edu"
                        },
                        {
                            "name": "Matthew J Weinstock, MD",
                            "role": "CONTACT",
                            "email": "mweinsto@bidmc.harvard.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Karmanos Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Detroit",
                    "state": "Michigan",
                    "zip": "48201",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Grace Bae, MPH, CCRP",
                            "role": "CONTACT",
                            "phone": "313-576-8030",
                            "email": "baeg@karmanos.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.33143,
                        "lon": -83.04575
                    }
                },
                {
                    "facility": "Masonic Cancer Center, University of Minnesota",
                    "status": "RECRUITING",
                    "city": "Minneapolis",
                    "state": "Minnesota",
                    "zip": "55455",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Joseph Maakaron, MD",
                            "role": "CONTACT",
                            "email": "maaka001@umn.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.97997,
                        "lon": -93.26384
                    }
                },
                {
                    "facility": "Washington University School of Medicine",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Katherine Stricker",
                            "role": "CONTACT",
                            "email": "kstricker@wustl.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "John Theurer Cancer Center",
                    "status": "RECRUITING",
                    "city": "Hackensack",
                    "state": "New Jersey",
                    "zip": "07601",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Elizabeth McCarthy",
                            "role": "CONTACT",
                            "email": "elizabethl.mccarthy@hmhn.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.88593,
                        "lon": -74.04347
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Anthony Zisa",
                            "role": "CONTACT",
                            "email": "zisaa@mskcc.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Cleveland Clinic",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44195",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Asala Issa",
                            "role": "CONTACT",
                            "email": "issaa@ccf.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "University of Pennsylvania, Abramson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Stefan Barta, MD",
                            "role": "CONTACT",
                            "email": "Stefan.barta@pennmedicine.upenn.edu"
                        },
                        {
                            "name": "Allison Nelson",
                            "role": "CONTACT",
                            "email": "Allison.Nelson@pennmedicine.upenn.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "Fox Chase Cancer Center",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19111",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Allandria Straker-Edwards",
                            "role": "CONTACT",
                            "email": "allandria.straker-edwards@fccc.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008223",
                    "term": "Lymphoma"
                },
                {
                    "id": "D000006689",
                    "term": "Hodgkin Disease"
                },
                {
                    "id": "D000016399",
                    "term": "Lymphoma, T-Cell"
                },
                {
                    "id": "D000016411",
                    "term": "Lymphoma, T-Cell, Peripheral"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                },
                {
                    "id": "D000008228",
                    "term": "Lymphoma, Non-Hodgkin"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14850",
                    "name": "Recurrence",
                    "relevance": "LOW"
                },
                {
                    "id": "M18829",
                    "name": "Lymphoma, T-Cell",
                    "asFound": "T-cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18833",
                    "name": "Lymphoma, T-Cell, Peripheral",
                    "asFound": "Peripheral T-cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9751",
                    "name": "Hodgkin Disease",
                    "asFound": "Hodgkin Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M11222",
                    "name": "Lymphoma, Non-Hodgkin",
                    "relevance": "LOW"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4496",
                    "name": "Peripheral T-cell Lymphoma",
                    "asFound": "Peripheral T-cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2817",
                    "name": "Hodgkin Lymphoma",
                    "asFound": "Hodgkin Lymphoma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003520",
                    "term": "Cyclophosphamide"
                },
                {
                    "id": "C000024352",
                    "term": "Fludarabine"
                },
                {
                    "id": "D000007376",
                    "term": "Interleukin-2"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000019653",
                    "term": "Myeloablative Agonists"
                },
                {
                    "id": "D000018712",
                    "term": "Analgesics, Non-Narcotic"
                },
                {
                    "id": "D000000700",
                    "term": "Analgesics"
                },
                {
                    "id": "D000018689",
                    "term": "Sensory System Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "asFound": "Effect of",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M283230",
                    "name": "Fludarabine",
                    "asFound": "Rate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10411",
                    "name": "Interleukin-2",
                    "asFound": "Reconstruction",
                    "relevance": "HIGH"
                },
                {
                    "id": "M225513",
                    "name": "Fludarabine phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4032",
                    "name": "Analgesics",
                    "relevance": "LOW"
                },
                {
                    "id": "M20786",
                    "name": "Analgesics, Non-Narcotic",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                }
            ]
        }
    },
    "hasResults": false
}